Novartis Confirms Zolgensma Tumors
I denne episoden
- Novartis Confirms Zolgensma Tumors
- Evommune Buys Hinova Degrader
- T-Therapeutics Raises Series B
- Santersus Starts NUC-CAP Trial
- Sanofi Drops Nurix Program
- Octane And Currus Automate CUR-001
Kilder
- BioSpace: Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
- Techtimes: Novartis Confirms Zolgensma Caused Tumors in Two Children Via Gene Therapy Vector Integration - Tech Times
- BioSpace: Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gap
- BioSpace: T-time: British biotech pours $133M into the pot for bispecifics
- Pharmatimes: Santersus advances nucleoCapture into pivotal sepsis study
- Techtimes: Sepsis Device Enters Pivotal 350-Patient Trial by Removing DNA Immune Traps From Blood - Tech Times
- BioSpace: Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
- Pharmatimes: Octane and Currus automate CUR‑001 manufacturing on cocoon platform
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.